Program

Monday, September 19, 2016

Session A - HIV "Cure" Research with Emphasis on Viral Suppression

To tackle HIV persistence in patients on antiretroviral treatment, this session provides an opportunity for leading scientists working on HIV cure to share ideas and debate in order to accelerate research on viral reservoirs and latency as the way towards achieving a cure for HIV infection. World experts in the field will present their findings, and a panel discussion among all presenters will close the session.

Chairpersons and Discussants:

Carl Dieffenbach, PhD, Division of AIDS, National Institute of Allergy and Infectious Diseases
Anders Vahlne, MD, PhD, Karolinska Institutet

Speakers:

Robert Siliciano, MD, PhD, Johns Hopkins University
Guido Poli, MD, Vita-Salute San Raffaele University
Steven Wolinsky, MD, Northwestern University
Bruce Walker, MD, Ragon Institute of MGH, MIT, and Harvard
Tim Schacker, MD, University of Minnesota
Victor Garcia-Martinez, PhD, University of North Carolina
Jonathan Karn, PhD, Case Western Reserve University
Fabio Romerio, PhD, Institute of Human Virology
Ashley Haase, MD, Institute for Molecular Virology, University of Minnesota

Special Panel Discussion on HIV Cure Research (40 minutes) - chaired by Drs. Carl Diffenbach and Robert Gallo

Session B - Selected New Developments in Cancer Research

The persistent risk for cancers associated with HIV, despite effective treatment for the underlying immune deficiency, suggests a direct role for HIV in the pathogenesis of these malignancies. The presentations will investigate these relationships as well as the role of other infectious agents, including viruses and non-viral pathogens.  In addition, recent findings on how microbiota can increase or decrease cancer susceptibility and progression by diverse mechanisms will be presented.

Chairpersons and Discussants:

Eduardo Sotomayor, MD, George Washington University School of Medicine & Health Sciences
Franco Buonaguro, MD, Istituto Nazionale Tumori

Speakers:

Riccardo Dalla-Favera, MD, Columbia University
Gary Borisy, PhD, The Forsyth Institute
Robert Burk, MD, Albert Einstein College of Medicine
Bernhard Fleckenstein, MD, Universitatsklinikum Erlangen
Jeff Schlom, PhD, National Cancer Institute

Session C - Emerging Viruses and the Global Virus Network

Today’s highly mobile, interdependent, and interconnected world provides myriad opportunities for the rapid spread of infectious diseases. This session will focus on global health security within the context of emerging viral diseases such as Zika, Ebola, MERS, Polio, etc. Understanding and strengthening of capacity to respond to these infections is imperative to assessment of such new threats going forward.

Chairpersons and Discussants:

José Esparza MD, PhD, Adjunct Professor, Institute of Human Virology

Speakers:

Jerome Kim, MD, International Vaccine Institute
Scott Weaver, PhD, Institute for Human Infections and Immunity, University of Texas
Alan Schmaljohn, PhD, University of Maryland School of Medicine
Roger Glass, MD, NIH Fogarty
Konstantin Chumakov, PhD, U.S. Food and Drugs Administration
Ab Osterhaus, PhD, University of Veterinary Medicine, Hannover
Diane Griffin, MD PhD, Johns Hopkins

Tuesday, September 20, 2016

Session D – Structural Biology

This session reviews recent advances in the structural biology of HIV and other viruses, focusing on the molecular mechanisms of viral entry, assembly, budding, and maturation, as well as an emphasis on the development of new therapeutics and preventative approaches.

Chairpersons and Discussants:

Eric Sundberg, PhD, Institute of Human Virology
Leonid Margolis, PhD, National Institute of Child Health and Human Development

Speakers:

Stefan Sarafianos, PhD, University of Missouri
Andrew Ward, PhD, Scripps Research Institute
Sriram Subramaniam, PhD, National Cancer Institute
Peijun Zhang, PhD, Scripps Research Institute
Marzena Pazgier, PhD, Institute of Human Virology
Jason McLellan, PhD, Dartmouth University
Bing Chen, PhD, Harvard University
Joseph Sodroski, MD, Harvard University
Gregory Melikian, PhD, Emory University
Carol Weiss, MD PhD, Food and Drug Administration
Pamela Bjorkman, PhD, California Institute of Technology    

Session E – Extracellular Vesicle Research

Chairpersons and Discussants:

Thomas Lehner, MD, Kings College London
Isaac Witz, PhD, Tel Aviv University

Speakers:

Leonid Margolis, PhD, National Institute of Child Health and Development
Fatah Kashanchi, PhD, George Mason University
Dirk Dittmer, PhD, University of North Carolina
Howard Fox, MD, PhD, University of Nebraska
Esther N.M. Nolte-t Hoen, PhD, Utrecht University

Session F - Immunology and Viral Pathogenesis Research

Innate and adaptive immune responses play a role in controlling viral replication. Yet, immune dysfunction is common in HIV-infected individuals, and the virus has developed multiple strategies to evade host defenses.  New findings on the pathogenesis of HIV and other viral infections and their implications for treatment strategies will be presented.

Chairpersons and Discussants:

Guido Poli, MD, Vita-Salute San Raffaele University
Arnaldo Caruso, MD, University of Bresia

Speakers:

Louis Picker, MD, Vaccine and Gene Therapy Institute, OHSU
Warner Greene, MD PhD, Gladstone Institute, University of California San Francisco
Paolo Lusso, MD PhD, National Institute of Allergy and Infectious Diseases
Jeff Lifson, MD, National Cancer Institute
Tim Fouts, PhD, Profectus Biosciences
John Mellors, MD, University of Pittsburgh

Wednesday, September 21, 2016

Session G - Progress in Vaccinology and HIV Prevention

Progress in achieving an effective HIV vaccine has been thwarted by the high variability of the virus and an inability to achieve sustainable immune responses to key viral antigens.  Of particular interest is the application of new technologies to create more stable structures that will block viral entry and optimize broadly neutralizing antibodies.  In addition to vaccinology, this session includes current updates on antiretroviral-based prevention strategies.

Chairpersons and Discussants:

Robert C. Gallo, MD, Director, Institute of Human Virology
Georgia Tomaras, PhD, Duke Human Vaccine Institute

Speakers:

Don Forthal, MD, University of California Irvine
Margie Ackerman, PhD, Dartmouth University
Gabriel Victora PhD, Whitehead Institute
Thomas Hope, PhD, Northwestern University
Anthony Devico, PhD, Institute of Human Virology
Chris Parks, PhD, IAVI
Garnett Kelsoe, DSc, Duke University
Michel Nussenzweig, MD, PhD, The Rockefeller University
Jeff Ravetch, MD, PhD, The Rockefeller University
Cythnia Derdeyn, PhD, Emory University
F. Eun-Hyung Lee PhD, Emory University
Susan Buchbinder, MD, University of California San Francisco
Ken Mayer, MD, Fenway Institute, Harvard University

Session H – Lifetime Achievement Award Mini-Symposium

Chairpersons and Discussants:

Robert C. Gallo, MD, Director, Institute of Human Virology

Speakers:

Robert C. Gallo, MD, Director, Institute of Human Virology
Robin Weiss, MD PhD, University College London
Carlo Croce, MD, Institute of Genetics, Ohio State University
Harald Zur Hausen, MD
Peter Vogt, PhD, The Scripps Research Institute, The 2016 IHV Lifetime Achievement Award for Scientific Contributions
Mario Stevenson, PhD, University of Miami Miller School of Medicine
Harvey Alter, MD, NIH Clinical Center
Ray Schinazi, PhD, Emory University, The 2016 IHV Lifetime Achievement Award for Public Service

Thursday, September 22, 2016

Session I - Advances in Clinical Virology

This session covers recent cutting edge updates on the treatment and management of HIV, Hepatitis C, and Hepatitis B infections with particular emphasis on co-morbid conditions such as metabolic syndromes, cardiovascular complications and the use of therapeutic antibodies.

Chairpersons and Discussants:

Shyam Kottilil, MD, Institute of Human Virology
John Bartlett, MD, Johns Hopkins University
Ed Tramont, MD, National Institutes of Health, NIAID
Robert Redfield, MD, Institute of Human Virology

Speakers:

John Bartlett, MD, Johns Hopkins University School of Medicine
Michael Saag, MD, University of Alabama
Mark Wainberg, MD, McGill University
Barry Peters, MD, King's College London
Mark Sulkowski, MD, Johns Hopkins University
Shyam Kottilil, MD, Institute of Human Virology
Anu Osinusi, MD, MPH, Gilead Sciences
Peter Stock, MD, University of California San Francisco
Joanna Suzich, PhD, MedImmune
Closing Remarks Dr. Gallo